Esophagus-sparing radiotherapy for complicated spinal metastases (ESO-SPARE). A randomized phase III clinical trial
Esophagus-sparing VMAT/IMRT did not reduce peak dysphagia in the intention-to-treat analysis but showed a significant benefit in the per-protocol analysis. Higher esophageal dose and larger irradiated volumes correlated with risk of "severe-or-worse" dysphagia, suggesting that esophagus/pharynx-sparing RT may particularly benefit patients receiving high-dose, large-field radiation.
Authors
- Laura Ann Rechner (ORCID: https://orcid.org/0000-0002-0623-4495)
- Michael R. T. Laursen (ORCID: https://orcid.org/0000-0003-2964-4347)
- Patrik Sibolt (ORCID: https://orcid.org/0000-0001-8621-7777)
- Katrine Smedegaard Storm (ORCID: https://orcid.org/0000-0002-8091-3533)
- Gitte Fredberg Persson (ORCID: https://orcid.org/0000-0002-3363-3256)
- Morten Hiul Suppli (ORCID: https://orcid.org/0000-0003-1051-2766)
- Ivan R. Vogelius (ORCID: https://orcid.org/0000-0002-8877-1218)
- Anna Mann Nielsen
- V. Gram
- Wiviann Ottosson (ORCID: https://orcid.org/0000-0002-7167-0007)
- Sebastian Moretto Krog (ORCID: https://orcid.org/0000-0003-0023-8011)
Institutions
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1016/j.radonc.2025.110906
- Citations
- 2
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Rigshospitalet
- Siemens Healthineers